By accepting you will be accessing a service provided by a third-party external to https://i3health.us/

Atezolizumab/Bevacizumab Approved for Unresectable Hepatocellular Carcinoma

The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who have not previously received systemic therapy.The approval was based on IMbrave150 (NCT03434379), a phase 3 trial that enrolled 501 patients with unresectable HCC. Patients were randomized in a 2:1 ratio to receive atezolizumab 1,200 mg administered intravenously followed by bev...

Ramucirumab/Erlotinib Approved: Metastatic Non-Small Cell Lung Cancer

The FDA has approved ramucirumab (Cyramza®, Eli Lilly and Company) in combination with erlotinib for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 substitution mutation.The approval was based on RELAY (NCT02411448), a phase 3 trial that enrolled 449 patients with untreated stage IV NSCLC. Eligible patients were at least 18 years old, had an Eastern Cooperative Oncology Group (ECOG) perfor...

Atezolizumab for PD-L1–High Non-Small Cell Lung Cancer: David Spigel, MD

Atezolizumab (Tecentriq®, Genentech, Inc.) was recently approved by the FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high expression of programmed death ligand-1 (PD-L1). The approval was based on IMpower110, a phase 3 trial led by David Spigel, MD, Chief Scientific Officer and Director of the Lung Cancer Research Program at Sarah Cannon Research Institute in Nashville, Tennessee. In this interview with i3 Health, Dr. Spigel discusses the s...

TNBC: Metronomic Capecitabine Maintenance Improves Outcomes

Metronomic capecitabine maintenance after standard treatment has been shown to be a successful therapy for patients with triple-negative breast cancer (TNBC) in a recent study. Results of this study will be reported on later this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.Relapse and unfavorable outcomes are still issues among patients with TNBC. According to lead study author XI Wang, MD of the Department of Breast Oncology at Sun Yat-Sen University...

Selinexor/Bortezomib/Dexamethasone Effective for Relapsed/Refractory Multiple Myeloma

In patients with multiple myeloma who have received one to three previous therapies, selinexor/bortezomib/dexamethasone (SVd) significantly improves outcomes compared with bortezomib/dexamethasone (Vd) alone, according to results of the phase 3 BOSTON trial to be presented this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.The trial enrolled 402 patients with multiple myeloma who had received one to three prior therapies. Patients were stratified based ...

Copyright © 2020 i3 Health. All rights reserved.